Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials | SpringerLink
Systemic chemotherapy of breast cancer: adjuvant and neoadjuvant Systemic chemotherapy of breast cancer: adjuvant and neoadjuvant Alexandru Eniu, MD, PhD. - ppt download
Comparative hematological profiles for dose‑dense vs. regular anthracycline‑based neoadjuvant chemotherapy in non‑metastatic breast cancer
Adjuvante Chemotherapie beim Mammakarzinom - 07 - 2010 - Heftarchiv - AMT
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients | PLOS ONE
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
Cancers | Free Full-Text | Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial - The Lancet Oncology
1607-Breast adjuvant AC (DOXOrubicin and CYCLOPHOSPHamide) dose dense followed by PACLitaxel dose de | eviQ
PDF) A randomised pilot Phase II study of doxorubicin and cyclophosphamide ( AC) or epirubicin and cyclophosphamide (EC) given 2 weekly with pegfilgrastim (accelerated) vs 3 weekly (standard) for women with early breast
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial - The Lancet
Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials - The Lancet
Does dose-dense neoadjuvant chemotherapy have clinically significant prognostic value in breast cancer?: A meta-analysis of 3,724 patients | PLOS ONE
ESMO 2022: Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial - ScienceDirect
Impact of dose-dense neoadjuvant chemotherapy on pathologic response and survival for HER2-positive breast cancer patients who receive trastuzumab | npj Breast Cancer
Survival outcomes for dose‐dense paclitaxel plus carboplatin neoadjuvant vs standard adjuvant chemotherapy in stage II to III triple‐negative breast cancer: A prospective cohort study with propensity‐matched analysis - Xiu - 2022 -
Dose-dense chemotherapy for breast cancer: what does the future hold? | Future Oncology
![PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/cad0421203b35bdec3bcffd87abb3ca1fd4c1ef4/6-Figure2-1.png "PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar")
PDF] Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial | Semantic Scholar
